Evidence map›Paper›PMID 35528556›Full record

ArticleRSC advances2019

A highly selective fluorescent probe for human NAD(P)H:quinone oxidoreductase 1 (hNQO1) detection and imaging in living tumor cells.

Ya Zhu, Jialing Han, Qian Zhang, Zhou Zhao, Jin Wang, Xiaowei Xu, Haiping Hao, Jun Zhang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ya ZhuSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Jialing HanSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Qian ZhangSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Zhou ZhaoSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Jin WangSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Xiaowei XuSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.ORCID https://orcid.org/0000-0003-1886-2728
Haiping HaoSchool of Pharmacy, China Pharmaceutical University 210009 Nanjing China xw@cpu.edu.cn haipinghao@cpu.edu.cn.
Jun ZhangSchool of Pharmacy, Nanjing Medical University 211166 Nanjing China zhangjun@njmu.edu.cn.
China Pharmaceutical University · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human NAD(P)H:quinone oxidoreductase (hNQO1) can be used as a biomarker for the early diagnosis of cancer. In this article, a novel fluorescent probe 1 for detecting hNQO1 was designed and synthesized by using 2-dicyanomethylene-3-cyano-4,5,5-trimethyl-2,5-dihydrofuran (TCF) derivative (TCF-OH) as a fluorophore and quinone propionic acid (QPA) as a recognition group. The probe, which has high selectivity for hNQO1 and a Stokes shift of about 117 nm, shows a linear relationship with hNQO1 concentrations in the range of 0.25-3 μg ml

Identifiers

PMID35528556
PMCPMC9070553
OpenAlexW4233225562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.